SynthesisBMC urology2025
Extended-spectrum beta-lactamase and carbapenemase-producing Gram-negative bacteria in urinary tract infections in Ethiopia: a systematic review and meta-analysis.
Synthesis in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Escherichia coli from patients, cattle, and environmental sources in northwest Amhara, Ethiopia: a one health approach.BMC microbiology · 2026Article
- Prevalence, antimicrobial susceptibility patterns of bacterial uropathogens and evaluation of urine dipstick parameter accuracy among individuals with diabetes in Ayder Comprehensive Specialized Hospital and Mekelle General Hospital, Tigray, Ethiopia.BMC infectious diseases · 2026Article
- Antimicrobial susceptibility and risk factors of asymptomatic bacteriuria among pregnant women attending antenatal care at public health facilities in Debre Markos town, Northwest Ethiopia.BMC microbiology · 2026Article
- Bacterial isolates and antibiotic resistance in critically ill sepsis patients at a tertiary hospital in Ethiopia.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infection (UTI) is one of the most common infections worldwide, particularly in developing countries. It also is among the most prevalent nosocomial infections, largely due to the widespread use of urinary catheters in hospitalized patients. These catheters often act as reservoirs for multidrug-resistant bacteria, including extended-spectrum beta-lactamase- and carbapenemase-producing pathogens, which significantly limit treatment options and delay appropriate care. This systematic review and meta-analysis, therefore, aimed to assess the pooled prevalence of ESBL- and carbapenemase-producing Gram-negative bacteria associated with UTIs in Ethiopia.
methodsA systematic literature search of all available electronic databases such as PubMed, Hinari, Google Scholar and EMBASE, Scopus, and African journal online was performed. The quality of the included studies was assessed via the Joanna Briggs Institute critical appraisal tool. The data were extracted from the eligible studies via Microsoft Excel 2019 and analysed via STATA version 17. The presence of between-study heterogeneity was checked via the Cochrane Q statistic, and the magnitude was quantitatively measured via I
resultsA total of 20 studies with 1010 and 557 Gram-negative bacterial isolates from 6263 and 2199 study participants for extended-spectrum beta-lactamase and carbapenemase, respectively, were included. The overall pooled prevalence rates of extended-spectrum beta-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Ethiopia were 30.92% (95% CI: 21.23-40.61, P < 0.001) and 15.12% (95% CI: -0.28-30.52, P < 0.001), respectively. The most common extended-spectrum beta-lactamase producers were Klebsiella spp., 43.91% (95% CI: 30.63-57.18, P < 0.001), followed by E. coli, 31.14% (95% CI: 21.27-41.01, P < 0.001). Similarly, the predominant carbapenemase producer was Klebsiella spp., 17.78% and E. coli, 11.42%.
conclusionand recommendations. In this meta-analysis, the pooled prevalence of extended-spectrum beta-lactamase- and carbapenemase-producing Gram-negative bacteria was significantly high. During the development of empiric treatment protocols for urinary tract infections, extended-spectrum beta-lactamase- and carbapenemase-producing uro-pathogens should not be underestimated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.